NCT02483234View on ClinicalTrials.gov

Psoriasis-Arthritis & Bone Program

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

June 30, 2018

Study Completion Date

September 30, 2018

Conditions
PsoriasisPsoriatic Arthritis
Interventions
DRUG

secukinumab

Trial Locations (1)

91054

University of Erlangen-Nuremberg, Erlangen

All Listed Sponsors
lead

University of Erlangen-Nürnberg Medical School

OTHER

NCT02483234 - Psoriasis-Arthritis & Bone Program | Biotech Hunter | Biotech Hunter